Skip to main navigation Skip to search Skip to main content

Pathogenic Variants in ATP1A3: Why Is There So Much Confusion?

  • Kathleen J. Sweadner
  • , Elena Arystarkhova
  • , Ihtsham U. Haq
  • , Allison Brashear
  • , Laurie J. Ozelius
  • Massachusetts General Hospital
  • University of Miami

Research output: Contribution to journal › Article › peer-review

Abstract

Dominant pathogenic variants in ATP1A3 can occur anywhere in the coding sequence and can cause a wide range of clinical presentations. A practical problem is that sequencing services use one of 3 different mRNA transcripts with different lengths to number the candidate variants. Genetic reports often identify an ATP1A3 variant as a VUS when it is actually well validated. Only 1 transcript, the MANE Select transcript that encodes a protein of 1, 013 amino acids, is well supported by evidence. Misidentification of variants in ATP1A3 is disadvantageous when it prevents a confident diagnosis. We illustrate the differences among the 3 transcripts and their merits. Sequencing services should use the MANE Select transcript.

Original languageEnglish
Article numbere200320
JournalNeurology: Genetics
Volume11
Issue number6
DOIs
StatePublished - Dec 2025

Fingerprint

Dive into the research topics of 'Pathogenic Variants in ATP1A3: Why Is There So Much Confusion?'. Together they form a unique fingerprint.

Cite this